A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study

Press/Media: Press / Media

PeriodNov 16 2016

Media coverage

1

Media coverage

  • TitleA Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date11/16/16
    PersonsEric J Lawitz
View all 1
View less